STOFF 2022

Society for Translational Oncology Fellows’ Forum (STOFF) was an intensive 3-day workshop that occurred Thursday, August 18 – Saturday, August 20, 2022, bringing together 25 fellows and junior faculty within 5 years of training completion from leading medical, surgical, radiation, and pediatric oncology groups and subspecialty fellowships to educate these rising stars on issues around and barriers to successful translational cancer research.

Congratulations to our 2022 Fellows
Our Fellows | Our Faculty | Agenda

This forum is internationally acclaimed for its focused, practical, and personal approach. It provides guidance to oncology fellows and junior faculty regarding how to apply translational research findings in tumor biology to improve patient outcomes. The broad-based curriculum covers a range of topics related to new drug development.

A special thank you to the 2022 STOFF co-chairs Dr. Keith Flaherty (Massachusetts General Hospital/Harvard Medical School), Dr. Ross Levine (Memorial Sloan Kettering Cancer Center), and Dr. Stacey Berg (Baylor College of Medicine/Texas Children’s Cancer Center) for their leadership and direction.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Select 2022 Presentation Summaries

PI Role and Conflict of Interest
Fellow summary authored by Rafi Winograd, MD, PhD

Working with Industry
Fellow summary authored by Xiaolin Zhu, MD, PhD

Science at the Interface Between the Laboratory and the Clinic
Fellow summary authored by Yuki Kagoya, MD, PhD

Phase I/II Clinical Trials: Protocol Development/Hypothesis Testing
Fellow summary authored by Caner Saygin, MD

Career Development in Academia
Fellow summary authored by Julia Foldi, MD, PhD

Issues in Design of Translational Research Trials
Fellow summary authored by James Smithy, MD, MHS

Therapeutic Resistance Including Serial Biopsy, Rapid Autopsy and Blood-based Biomarkers Platforms
Fellow summary authored by Jamie Schneider, MD, PhD

Immune Checkpoint Inhibition in Advanced Cancer
Fellow summary authored by Quaovi Sodji, MD, PhD

Oncology Drug Development: A Regulatory Perspective
Fellow summary authored by Christopher Devine, MD, MBA

Systemic Toxicity Associated With Immune Checkpoint Inhibitors
Fellow summary authored by James Smithy, MD, MHS

New Drug Development in 2022: Progress, Challenges, and Prices
Fellow summary authored by Christopher Devine, MD, MBA